- Athabasca Nuclear Corp. (TSX-V: ATNC) raised $22 million CAD at $0.55/share, targeting high-grade uranium exploration in Saskatchewan’s Athabasca Basin.
- NeuraBridge Health Inc. (CSE: NRBH) raised $12 million CAD at $1.25/share, offering an AI diagnostic platform with $1.7 million in existing revenue.
- Insider lockups run until January 4, 2027 for ATNC and March 2, 2027 for NRBH, limiting near-term selling pressure on both new issues.
- Both deals were anchored by institutional buyers — a European uranium royalty fund and a Toronto life sciences family office — signalling quality support.
Two new listings arrived on Canadian junior exchanges this week, testing investor appetite as the TSX Composite fell 1.23% to 35,826 on September 2, 2026 — part of a broader risk-off session that also dragged the S&P 500 down 0.71% and the NASDAQ 1.03%. Despite the headwinds, both issuers priced at the top of their respective ranges, a signal that institutional demand held firm ahead of the open.
Athabasca Nuclear Corp. (TSX-V: ATNC) — Uranium Exploration, Saskatchewan
Athabasca Nuclear Corp. launched on the TSX Venture Exchange at $0.55 per share, raising $22 million CAD through a offering of 40 million shares. The Saskatoon-based explorer holds four contiguous claim blocks — totalling 187,000 hectares — in the western Athabasca Basin, the world’s highest-grade uranium district. The company’s flagship Clearwater North project sits 38 kilometres southwest of Cameco’s McArthur River operation, the planet’s largest high-grade uranium mine.
Athabasca Nuclear’s management team includes former Denison Mines geologists and a CEO with 22 years of Basin-specific exploration experience. The company is not yet producing revenue; it is a pure-play exploration vehicle targeting a maiden drill program in Q1 2027. For retail investors, this is a high-risk, high-optionality bet on uranium prices — spot uranium traded near US$94/lb (approximately CAD $130.55/lb at the current USD/CAD rate of 1.3888) as of late August 2026.
Underwriting was led by Haywood Securities, with Canaccord Genuity and PI Financial participating as co-underwriters. Institutional support includes a $4.2 million CAD strategic placement from a European uranium royalty fund. The standard 4-month-and-one-day hold period applies to all escrowed shares, meaning insiders and seed shareholders cannot sell before approximately January 4, 2027. The offering was structured with full warrants at $0.80 per share exercisable for 24 months, giving retail buyers additional upside leverage if the stock gains traction.
NeuraBridge Health Inc. (CSE: NRBH) — AI-Powered MedTech, Ontario
NeuraBridge Health Inc. opened on the Canadian Securities Exchange at $1.25 per share, raising $12 million CAD through 9.6 million shares. The Toronto-based company has built a proprietary AI diagnostic platform that analyzes continuous glucose monitor (CGM) and wearable biosensor data to flag early-stage metabolic dysfunction — including pre-diabetes and non-alcoholic fatty liver disease — before clinical symptoms appear. In plain terms: NeuraBridge sells a software-as-a-service layer that sits on top of existing wearable hardware and flags health risks earlier than standard screening protocols.
The company already holds pilot contracts with two Ontario regional health authorities and a letter of intent with a national pharmacy benefits manager covering an estimated 310,000 plan members. Revenue for the fiscal year ending June 30, 2026 was $1.7 million CAD, with management projecting $6.4 million CAD in fiscal 2027 as pilot programs convert to full deployments. This is an early-stage but revenue-generating company — a meaningful distinction from pre-revenue exploration issuers.
Echelon Capital Markets served as sole bookrunner, with Eight Capital providing fairness advisory services. A $2.5 million CAD portion of the raise was anchored by a Toronto-based life sciences-focused family office. Insider shares are subject to a 6-month voluntary escrow agreed to at the time of listing, pushing the earliest insider sell date to approximately March 2, 2027. No warrants were attached to the public offering, keeping the capital structure cleaner than many CSE debut deals. Minimum board lot is 100 shares, making the entry point accessible at $125 CAD for a standard position.
Market Context for New Listings
Both issuances closed their subscription periods in late August, before this week’s equity softness. The timing is a reminder that IPO pricing reflects conditions at bookbuild close, not the trading debut. Retail investors buying in the secondary market on September 2 were effectively entering into a down-tape environment, which can create early entry opportunities — or early paper losses — depending on how sentiment shifts in September. The TSX Composite’s 1.23% single-day decline was driven largely by energy and financials; neither uranium exploration nor MedTech SaaS were primary drivers of the selloff, offering some sector-specific insulation for these new names.
